德纳维制药（DVAX）今日盘前股价大涨37.56%，引发市场广泛关注。
消息面上，法国制药巨头赛诺菲宣布将以每股15.50美元的现金价格收购德纳维制药，总交易价值约22亿美元。这一报价较德纳维制药周二收盘价溢价39%，直接推动了股价的飙升。
通过此次收购，赛诺菲将获得德纳维制药已在美国上市的乙肝疫苗及处于早期试验阶段的带状疱疹疫苗，进一步强化其在成人疫苗领域的布局。该交易预计将于2026年第一季度完成，赛诺菲表示不会影响其2025年财务指引。
德纳维制药（DVAX）今日盘前股价大涨37.56%，引发市场广泛关注。
消息面上，法国制药巨头赛诺菲宣布将以每股15.50美元的现金价格收购德纳维制药，总交易价值约22亿美元。这一报价较德纳维制药周二收盘价溢价39%，直接推动了股价的飙升。
通过此次收购，赛诺菲将获得德纳维制药已在美国上市的乙肝疫苗及处于早期试验阶段的带状疱疹疫苗，进一步强化其在成人疫苗领域的布局。该交易预计将于2026年第一季度完成，赛诺菲表示不会影响其2025年财务指引。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.